Expert Firm Urges CS Disco Inc. Investors to Seek Legal Counsel Before Key Deadline in Securities Class Action Lawsuit

ROSEN, A RESPECTED AND LEADING FIRM, Encourages CS Disco, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LAW NEW YORK, Oct. 29, 2023 (GLOBE NEWSWIRE) Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of CS Disco, Inc. (NYSE: LAW) between July 21, 2021 and…

Read More

Act Now: Protect Your Investment in Discover Financial Services – A Message from Rosen, a Trusted Law Firm

The Importance of Seeking Counsel as a Discover Financial Services Investor Understanding the October 31 Deadline As the October 31, 2023 deadline approaches for Discover Financial Services (DFS) investors, it is crucial to be aware of the potential implications of the lead plaintiff deadline. Rosen Law Firm, a respected global investor rights law firm, is…

Read More

Calling All Kenvue Inc. Investors: Don’t Miss Out on Your Chance for Justice! A Top-Ranked Law Firm Urges You to Get Legal Backup Before It’s Too Late in Securities Class Action

Welcome to the Wild World of Securities Litigation Hold on to your hats, folks – it’s about to get legal up in here! So, you may have heard about the recent reminder from the Rosen Law Firm regarding Kenvue Inc. investors and the impending deadline in securities litigation. The world of IPOs and securities can…

Read More

Uncovering the Truth: Pomerantz Law Firm Investigates Claims Against Adobe Inc. on Behalf of Shareholders

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adobe, Inc. – ADBE NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Adobe, Inc. (“Adobe” or the “Company”) (NASDAQ: ADBE). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529,…

Read More

Breaking News: FDA Approves Loqtorzi (Toripalimab TPZI) for All Stages of Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) – A Major Milestone for Coherus and Junshi Biosciences

Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) LOQTORZI™ (toripalimab-tpzi) Carton LOQTORZI is the first and only FDA-approved treatment for NPC LOQTORZI™ (toripalimab-tpzi) has been making waves in the medical community as the first and only FDA-approved treatment for Nasopharyngeal Carcinoma (NPC). This new drug, indicated in combination with chemotherapy for 1st line…

Read More